



JFW
DAC

PATENT APPLICATION
U.S. Appln. No. 10/574,437
Attorney Docket No. 51825-US-PCT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below identified date.

Kara Shure
Kara Shure

September 22, 2009
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Paolo Costantino et al.	Confirmation No.:	9723
Serial No.:	10/574,437	Group Art Unit:	1645
Intl. Appln. No.:	PCT/IB2004/003366	Examiner:	Not yet assigned
I.A. Filing Date:	04 October 2004		
For:	HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES		

REPLY TO NOTIFICATION OF DEFECTIVE RESPONSE

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Notification of Defective Response mailed 27 August 2007, enclosed herewith are the following documents:


1. **RETURN COPY** of Notification of Defective Response.
2. **PETITION UNDER 37 C.F.R. § 1.497(d)** w/Statement of Francesco Berti, Processing Fee under 37 CFR 1.17(i) of \$130.00, Copy of Consent By Assignee for Change of Inventorship, Copy of Assignment with Notice of Recordation and Copy of Declaration For Patent Application.
3. **RETURN RECEIPT POSTCARD.**

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: 22 September 2005

By: 

Helen Lee

Registration No. 39,270

Customer No. 27476

NOVARTIS VACCINES AND DIAGNOSTICS, INC.


Intellectual Property

P.O. Box 8097

Emeryville, CA 94662-8097

Tel (510) 923-8406

Fax (510) 655-3542



COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/574,437	FIRST NAMED APPLICANT Paolo Costantino	ATTY. DOCKET NO. PP021389.0013
---	---	-----------------------------------

27476
 NOVARTIS VACCINES AND DIAGNOSTICS INC.
 INTELLECTUAL PROPERTY R338
 P.O. BOX 8097
 Emeryville, CA 94662-8097

INTERNATIONAL APPLICATION NO. PCT/IB04/03366	
I.A. FILING DATE 10/04/2004	PRIORITY DATE 10/02/2003

EMERYVILLE - CIP					
AUG 31 2007					
F/F	M/D	Inv.	RF	ASG	PA

CONFIRMATION NO. 9723
 371 FORMALITIES LETTER

 OC000000025551070

Date Mailed: 08/27/2007

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Priority Document
- Copy of the International Application filed on 04/03/2006
- Copy of the International Search Report filed on 04/03/2006
- Oath or Declaration filed on 04/25/2007
- U.S. Basic National Fees filed on 04/03/2006
- Priority Documents filed on 04/03/2006

DOCKETED on/by 9/5/07/mno
 Atty. HL PA
 File # PP 21389.0013
 Due Date _____ Ext _____
 Final Date _____
51825-US-PCT

Applicant's response filed 04/25/2007 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 02/26/2007 have not been completed.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - The signed oath received April 25, 2007, listed Berti, Francesco as an inventor, however he is not listed on the published IA. Please submit a corrected oath or an explanation.

Applicant is required to complete the response within a time limit of **ONE MONTH** from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.

<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

VIRGINIA L IRBY

Telephone: (703) 308-9140 EXT 229

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/574,437	PCT/IB04/03366	PP021389.0013

FORM PCT/DO/EO/916 (371 Formalities Notice)



PATENT
Attorney Docket No.: 51825-US-PCT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below identified date.

Yes
Kara Shure

September 22, 2009
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Paolo Costantino et al.	Confirmation No.:	9723
Serial No.:	10/574,437	Group Art Unit:	1645
Intl. Appln. No.:	PCT/IB2004/003366	Examiner:	Not yet assigned
I.A. Filing Date:	04 October 2004		
For:	HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES		

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT
ABANDONED UNINTENTIONALLY UNDER 37 C.F.R. §1.137(b)**

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Petition for Revival of an Application Abandoned Unintentionally under 37 C.F.R. §1.137(b) is submitted in response to the Decision on Petition under 37 C.F.R. §1.181, which was mailed from the U.S. Patent and Trademark Office (U.S. PTO) on 15 September 2009.

It is indicated that the Decision on Petition that the above-identified application became abandoned for failure to file a proper reply to the Notification of Defective Response (Form PCT/DO/EO/916), which was mailed from the U.S. PTO 27 August 2007. It is also indicated in the Decision on Petition that Applicant did not file a petition under 37 C.F.R. §1.497(d) to add Francesco Berti as an inventor, but merely indicated that Francesco Berti should have been listed as an inventor and that the error occurred without deceptive intent.

The assignee, Novartis Vaccines and Diagnostics SRL, hereby petitions for revival of the above-identified application. Enclosed is the requisite petition fee set forth in 37 C.F.R.


§1.17(m) of \$ 1,620.00. Also enclosed is proper reply to the Notification of Defective Response and a Petition under 37 C.F.R. §1.497(d).

Since this application was filed on or after 08 June 1995, no terminal disclaimer is required.

The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 C.F.R. §1.137(b) was unintentional.

The Commissioner is hereby authorized to charge any deficiency or credit any overpayment in fees that may be due in this matter to Deposit Account No. 03-1664.

Respectfully submitted,
NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: 22 September 2005 By: 
Helen Lee
Registration No. 39,270

Customer No. 27476

Mailing Address:

Intellectual Property
P.O. Box 8097
Emeryville, CA 94662-8097
Tel: (510) 923-2192
Fax: (510) 655-3542



PATENT
Attorney Docket No.: 51825-US-PCT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below identified date.

KS
Kara Shure

September 22, 2009
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Paolo Costantino et al.	Confirmation No.:	9723
Serial No.:	10/574,437	Group Art Unit:	1645
Intl. Appln. No.:	PCT/IB2004/003366	Examiner:	Not yet assigned
I.A. Filing Date:	04 October 2004		
For:	HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES		

PETITION UNDER 37 C.F.R. §1.497(d)

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The presently named assignee, Novartis Vaccines and Diagnostics, SRL, hereby petitions for filing an oath or declaration pursuant to 35 U.S.C. §371(c)(4) naming an inventive entity different from the inventive entity set forth in the international stage. When the above-identified international application was filed, inventor "Francesco BERTI" was inadvertently omitted from the list of inventors without deceptive intent. Thus, assignee requests that inventor "Francesco BERTI" be added as an inventor in the above-identified international application. Inventors Paolo COSTANTINO and Francesco BERTI will be the true and correct inventive entity in the above-identified application in light of the currently pending claims once Francesco BERTI is added as a joint inventor.

To comply with the requirements of 37 C.F.R. §1.497(d), the following items are enclosed herewith:


1. Statement from Francesco Berti, indicating that the error in inventorship in the international application occurred without deceptive intention on his part;

2. Processing fee set forth in 37 C.F.R. §1.17(i) of \$130.00;
3. Copy of executed Consent By Assignee for Change of Inventorship; and
4. Copy of executed Declaration For Patent Application.

It is believed that the applicant has complied with requirements under 37 C.F.R. §1.497(d) and acceptance is requested of the declaration pursuant to 35 U.S.C. §371(c)(4) naming an inventive entity different from the inventive entity set forth in the international stage.

The Commissioner is hereby authorized to charge any deficiency or credit any overpayment in fees that may be due in this matter to Deposit Account No. 03-1664.

Respectfully submitted,
NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: 22 September 2005 By: 
Helen Lee
Registration No. 39,270

Customer No. 27476

Mailing Address:

Intellectual Property
P.O. Box 8097
Emeryville, CA 94662-8097
Tel: (510) 923-2192
Fax: (510) 655-3542



PATENT
Attorney Docket No.: 51825-US-PCT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below identified date.

Kara Shure
Kara Shure

September 22, 2009
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Paolo Costantino et al.	Confirmation No.:	9723
Serial No.:	10/574,437	Group Art Unit:	1645
Intl. Appln. No.:	PCT/IB2004/003366	Examiner:	Not yet assigned
I.A. Filing Date:	04 October 2004		
For:	HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES		

**STATEMENT BY FRANCESCO BERTI
AS REQUIRED BY 37 C.F.R. §1.497(d)**

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Francesco Berti, am an inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES,
which patent application was filed as International Application No. PCT/IB2004/003366 on 04 October 2004, and assigned U.S. Serial Number 10/574,437.

In the initial filing of this patent application, Paolo Costantino acted as principal inventor and interfaced with patent counsel and when the application was filed I was inadvertently omitted from the list of inventors. This error in inventorship in the international application occurred without deceptive intention on my part.

I hereby state that prior to executing the Declaration for Utility Patent Application in the above-identified application, I had reviewed and understood the contents of the above-identified specification, including the claims.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

18 Sep 03
Date

Francesco Berti
Francesco BERTI



PTO/SB/17i (07-09)

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROCESSING FEE
Under 37 CFR 1.17(i)
TRANSMITTAL

(Fees are subject to annual revision)

Send completed form to: Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

Application Number	PCT/IB2004/003366
Filing Date	04 October
First Named Inventor	Paolo COSTANTINO
Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	51825-US-PCT

Enclosed is a paper filed under 37 CFR 1.497(d) that requires a processing fee (37 CFR 1.17(i)).
Payment of \$ 130.00 is enclosed.

This form should be included with the above-mentioned paper and faxed or mailed to the Office using the appropriate Mail Stop, if applicable. For transmittal of petition fees under 37 CFR 1.17(f), (g) or (h), see form PTO/SB/17p.

Payment of Fees (small entity amounts are NOT available for the processing fees)

☒ The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 03-1664 :
☒ processing fee under 37 CFR 1.17(i) ☒ any deficiency of fees and credit of any overpayments

☐ Check in the amount of \$ _____ is enclosed.

☐ Payment by credit card (Form PTO-2038 or equivalent enclosed). Do not provide credit card information on this form.

**Processing Fees under 37 CFR 1.17(i): Fee \$130 Fee Code 1808 for all,
Except for § 1.221 papers (Fee Code 1803)**

For papers filed under:

- § 1.28(c)(3) - for processing a non-itemized fee deficiency based on an error in small entity status.
- § 1.41 - for supplying the name or names of the inventor or inventors after the filing date without an oath or declaration as prescribed by § 1.63, except in provisional applications.
- § 1.48 - for correcting inventorship, except in provisional applications.
- § 1.52(d) - for processing a nonprovisional application filed with a specification in a language other than English.
- § 1.53(b)(3) - to convert a provisional application filed under § 1.53(c) into a nonprovisional application under § 1.53(b).
- § 1.55 - for entry of late priority papers.
- § 1.71(g)(2) - to enter an amendment to the specification for purposes of 35 U.S.C. 103(c)(2) if not filed within the cited time periods
- § 1.99(e) - for processing a belated submission under § 1.99.
- § 1.103(b) - for requesting limited suspension of action, continued prosecution application (§ 1.53(d)).
- § 1.103(c) - for requesting limited suspension of action, request for continued examination (§ 1.114).
- § 1.103(d) - for requesting deferred examination of an application.
- § 1.217 - for processing a redacted copy of a paper submitted in the file of an application in which a redacted copy was submitted for the patent application publication.
- § 1.221 - for requesting voluntary publication or republication of an application. **Fee Code 1803**
- § 1.291(c)(5) - for processing a second or subsequent protest by the same real party in interest.
- § 1.497(d) - for filing an oath or declaration pursuant to 35 U.S.C. 371(c)(4) naming an inventive entity different from the inventive entity set forth in the international stage.
- § 3.81 - for a patent to issue to assignee, assignment submitted after payment of the issue fee.

Signature

Helen Lee

Typed or printed name

22 September 2005

Date

39,270

Registration No., if applicable

This collection of information is required by 37 CFR 1.17. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 5 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

COPY



PATENT
Attorney Docket No.: 51825-US-PCT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below identified date.

Kara Shure
Kara Shure

2 July 2009
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Paolo Costantino et al.	Confirmation No.:	9723
Serial No.:	10/574,437	Group Art Unit:	1645
Intl. Appln. No.:	PCT/IB2004/003366	Examiner:	Not yet assigned
I.A. Filing Date:	October 4, 2004		

For: HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR
SACCHARIDES

CONSENT BY ASSIGNEE FOR CHANGE OF INVENTORSHIP

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

NOVARTIS VACCINES AND DIAGNOSTICS, SRL, as successor and interest by change of name from Chiron SRL, a corporation duly organized under and pursuant to the laws of Italy and having its principal place of business at Via Fiorentina 1, Siena, Italy I-53100, is the assignee of the entire right, title and interest in the patent application identified above, as indicated on the Assignment filed April 25, 2007, and as recorded on Reel/Frame: 019220/0449, a copy of which is attached hereto.

NOVARTIS VACCINES AND DIAGNOSTICS, SRL hereby consents to the change of
inventorship of the subject patent application from "Paolo COSTANTINO" to
-- Paolo COSTANTINO and Francesco BERTI--.

2 July 2005
Date

Helen Lee

Name: Helen Lee
Title: Attorney-in-Fact
Novartis Vaccines and Diagnostics, SRL

NOVARTIS VACCINES AND DIAGNOSTICS, INC. COMPANY: INTELLECTUAL PROPERTY-R33



COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

APRIL 27, 2007

PTAS - KN

700322142A

700322142A

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
INTELLECTUAL PROPERTY-R338
P.O. BOX 8097
EMERYVILLE, CA 94662-8097UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENTTHE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF
THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS
AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER
REFERENCED BELOW.PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE
INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA
PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD
FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY
CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350.
PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE,
MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 04/25/2007

REEL/FRAME: 019220/0449
NUMBER OF PAGES: 5BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).
DOCKET NUMBER: PP021389.0013

ASSIGNOR:

COSTANTINO, PAOLO

DOC DATE: 03/26/2007

ASSIGNOR:

BERTI, FRANCESCO

DOC DATE: 03/27/2007

ASSIGNEE:

NOVARTIS VACCINES AND DIAGNOSTICS
SRL
VIA FIORENTINA, 1
I-53100 SIENA, ITALY

SERIAL NUMBER: 10574437

FILING DATE:

PATENT NUMBER:

ISSUE DATE:

TITLE: HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES

P.O. Box 1450, Alexandria, Virginia 22313-1450 - www.uspto.gov

USPTO

4/27/2007 8:13:24 PM PAGE 3/004 FAX 001V01

NOVARTIS VACCINES AND DIAGNOSTICS, INC. COMPANY: INTELLECTUAL PROPERTY-R33

019220/0449 PAGE 2

ASSIGNMENT SERVICES BRANCH
PUBLIC RECORDS DIVISION

ASSIGNMENT

WHEREAS, WE, PAOLO COSTANTINO and FRANCESCO BERTI, hereinafter referred to as *ASSIGNORS*, have invented certain new and useful improvements as described and set forth in the below-identified United Kingdom Patent Application, International Patent Application and application for United States Letters Patent:

Title: HYPO- AND HYPER- ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES

Date(s) of Execution: March 26 and 27, 2007

Priority Data:	<u>Application No.</u>	<u>Filing Date</u>
	GB 0323103.2	October 2, 2003
	PCT/IB2004/003366	October 4, 2004
	US 10/574,437	October 4, 2004

WHEREAS, NOVARTIS VACCINES AND DIAGNOSTICS SRL, with a place of business at Via Fiorentina 1, I-53100, Siena, Italy, hereinafter referred to as *ASSIGNEE*, is desirous of acquiring the entire right, title and interest in the above invention and application and in any Letters Patent which may be granted on the same;




NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that, for and in consideration of the sum of One Dollar (\$1.00) lawful money paid to *ASSIGNORS* by *ASSIGNEE*, receipt of which is hereby acknowledged, *ASSIGNORS* have sold, assigned and transferred, and by these presents do sell, assign and transfer unto said *ASSIGNEE*, and *ASSIGNEE'S* successors and assigns, all right, title and interest in and to the said invention, said application(s) and any Letters Patent which may hereafter be granted on the same in the United States and all countries throughout the world including any divisionals, renewals, continuations in whole or in part, substitutions, conversions (including conversions claiming priority under 35 U.S.C. §119(e)), reissues, prolongations or extensions thereof, the said interest to be held and enjoyed by said *ASSIGNEE* as fully and exclusively as it would have been held and enjoyed by said *ASSIGNORS* had this assignment and transfer not been made, to the full end and term of any Letters Patent.




PATENT

Atty. Docket No. PP021389.0013

ASSIGNORS further agree that they will, without charge to said **ASSIGNEE**, but at **ASSIGNEE'S** expense, cooperate with **ASSIGNEE** in the prosecution of said application and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as **ASSIGNEE** lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said **ASSIGNEE**, or **ASSIGNEE'S** successors and assigns.

IN TESTIMONY WHEREOF, **ASSIGNORS** have hereunto signed their name to this assignment on the date indicated below.

Date 26 March, 2007 
 PAOLO COSTANTINO

 Witness LORENZO TOLLERI

 Witness EUSA PASSANELLI

Date 27 MARCH, 2007 
 FRANCESCO BERTI

 Witness LORENZO TOLLERI

 Witness EUSA PASSANELLI



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DECLARATION FOR PATENT APPLICATION

☐ Supplemental (37 C.F.R. § 1.67)

As a named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name;

I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HYPO- AND HYPER- ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES

the specification of which (check one)

- ☐ is attached hereto.
- ☐ was filed on _____ as United States Application No. _____
- ☒ was filed on October 4, 2004 as International Application No. PCT/IB2004/003366 and assigned U.S. Application No. 10/574,437.
- ☐ and was amended on _____ (if applicable).

I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information known to me to be material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f), or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Claimed?	Certified Copy Attached?
0323103.2	GB	10/02/2003	Yes	

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor
 Residence (City, State)
 Citizenship
 Post Office Address
 Inventor's signature
 Date

Paolo COSTANTINO

Siena, Italy

Italy

c/o Novartis Vaccines and Diagnostics, Inc.
 P.O. Box 8097, Emeryville, California 94662-8097/US

Paolo Costantino
 26 March, 2007

Name of second inventor
 Residence (City, State)
 Citizenship
 Post Office Address
 Inventor's signature
 Date

Francesco BERTI

Siena, Italy

Italy

c/o Novartis Vaccines and Diagnostics, Inc.
 P.O. Box 8097, Emeryville, California 94662-8097/US

Francesco Berti
 27 MARCH, 2007

Name of third inventor
 Residence (City, State)
 Citizenship
 Post Office Address
 Inventor's signature
 Date

Name of fourth inventor
 Residence (City, State)
 Citizenship
 Post Office Address
 Inventor's signature
 Date